Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Houben, R; Schmid, CP; Maier, M; Wobser, M; Motschenbacher, S; Becker, JC; Vetter-Kauczok, CS; Weyandt, G; Hesbacher, S; Haferkamp, S.
p53 regulation by TRP2 is not pervasive in melanoma.
PLoS One. 2014; 9(1):e87440-e87440 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Autor/innen der Med Uni Graz:
Becker Jürgen Christian

Dimensions Citations:

Plum Analytics:
Number of Figures: 4
| | | |
p53 is a central tumor suppressor protein and its inhibition is believed to be a prerequisite for cancer development. In approximately 50% of all malignancies this is achieved by inactivating mutations in the p53 gene. However, in several cancer entities, including melanoma, p53 mutations are rare. It has been recently proposed that tyrosinase related protein 2 (TRP2), a protein involved in melanin synthesis, may act as suppressor of the p53 pathway in melanoma. To scrutinize this notion we analyzed p53 and TRP2 expression by immunohistochemistry in 172 melanoma tissues and did not find any correlation. Furthermore, we applied three different TRP2 shRNAs to five melanoma cell lines and could not observe a target specific effect of the TRP2 knockdown on either p53 expression nor p53 reporter gene activity. Likewise, ectopic expression of TRP2 in a TRP2 negative melanoma cell line had no impact on p53 expression. In conclusion our data suggest that p53 repression critically controlled by TRP2 is not a general event in melanoma.
Find related publications in this database (using NLM MeSH Indexing)
Blotting, Western -
Cloning, Molecular -
Humans -
Immunohistochemistry -
Intramolecular Oxidoreductases - metabolism
Melanoma - metabolism
RNA, Small Interfering - genetics
Signal Transduction - physiology
Tumor Suppressor Protein p53 - metabolism

© Meduni Graz Impressum